EE690 Assessing the Relative Budget Impact (BI) of PARP Inhibitor (PARPi) Combination Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) with and Without BRCA1/2 Mutations
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.955
https://www.valueinhealthjournal.com/article/S1098-3015(23)04085-8/fulltext
Title :
EE690 Assessing the Relative Budget Impact (BI) of PARP Inhibitor (PARPi) Combination Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) with and Without BRCA1/2 Mutations
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04085-8&doi=10.1016/j.jval.2023.09.955
First page :
Section Title :
Open access? :
No
Section Order :
10450